Our integrated antibody discovery and protein engineering platform enables the identification of unique epitopes and distinct combinations of biologics on an unprecedented scope and scale.
In three years, we have developed therapeutic candidates for 30+ targets in the immune synapse: novel, fully human antibodies, including multispecifics, engineered to be readily manufactured at scale. We’re advancing 15 therapeutic candidates in cancer, inflammation and autoimmune diseases through preclinical testing programs.
AN INTEGRATED, HIGH-THROUGHPUT PLATFORM
Our platform has several distinct advantages, including the ability to quickly generate highly diverse antibody sets, conduct novel biological screens, and interrogate multispecific constructs. That versatility enables the rapid discovery of high-quality therapeutic candidates; we are capable of drugging two new targets each month.